Amphastar Pharmaceuticals (AMPH) Presents At 20th Annual Needham Virtual Healthcare Conference

Company Overview - Amphastar is a biopharmaceutical company focused on developing and manufacturing technically challenging BLAs, NDAs, and ANDAs in injectable, inhalable, and intranasal formulations[37] - The company has a strong base business with approximately $350 million in 2020 revenue and approximately $143 million in 2020 gross profit[37] - Amphastar has a vertically integrated business model, from R&D to clinical trials, manufacturing, marketing, and distribution[6] Product Portfolio and Pipeline - The company has a diverse core of over 20 commercial products, including injectables and MDI products[11] - Amphastar has a robust pipeline of over 20 product candidates, including insulin products, in markets with barriers to entry[37] - Five filed ANDAs with IQVIA sales of approximately $2.4 billion, including AMP-002 with > $300 million IQVIA sales[23] - Five Inhalation ANDAs in development targeting products with IQVIA sales of approximately $8 billion[23] - Three candidates of Insulins with IQVIA sales ~$13 Billion[25] Financial Highlights - The company's net revenue has a CAGR of 13% from 2017 to 2020[14] - Self-funded R&D investment of approximately $280 million in the recent 5 years[18] - As of December 31, 2020, the company had $109684000 in cash, cash equivalents, restricted cash, and short-term investments[36]